Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Ammar A. Javed

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5463-5250; OpenAlex author ID A5086998230. Sources: OpenAlex.

Their work

Papers
106 (first author 9, last author 16)
Trials
0
Grants
0
Labs led
2
Collaborators
328
Papers, trials and grants by year

2016: 1 paper · 2017: 4 papers · 2018: 4 papers · 2019: 6 papers · 2020: 5 papers · 2021: 7 papers · 2022: 7 papers · 2023: 6 papers · 2024: 20 papers · 2025: 30 papers · 2026: 16 papers

Papers 50 of 106

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  3. Clinical and molecular features of resected early onset pancreatic ductal adenocarcinoma: insights from the NCDB and cBioPortal. Last author DOI 10.1016/j.hpb.2025.12.026↗
  4. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  5. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  6. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  7. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  8. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  9. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  10. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  11. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  12. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  13. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  14. Incidental Diagnosis of Pancreatic Cancer and Association with Improved Patient Outcomes: Assessing the Potential Clinical Use of Liquid Biopsy-Based Screening… Co-author DOI 10.1097/xcs.0000000000001721↗
  15. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336117↗
  16. Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study Last author DOI 10.21037/tgh-2026-0049↗
  17. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  18. Longitudinal assessment of disparities in pancreatic cancer care: A retrospective analysis of the National Cancer Database. Last author DOI 10.1002/wjs.12431↗
  19. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  20. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  21. Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis. Co-author DOI 10.1016/j.ejso.2025.109742↗
  22. Reply to: Comment on "Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A preva… Co-author DOI 10.1016/j.ejso.2025.110111↗
  23. Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.surg.2024.109114↗
  24. Pancreatic cancer. First author DOI 10.1016/s0140-6736(25)00261-2↗
  25. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  26. Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis. Co-author DOI 10.1093/jnci/djae294↗
  27. Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. First author DOI 10.1093/jnci/djaf037↗
  28. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  29. Surgical Resection of Murine PDAC Alters Hepatic Metastases and Immune Microenvironment. Co-author DOI 10.1097/mpa.0000000000002516↗
  30. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295↗
  31. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  32. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  33. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Last author DOI 10.1097/sla.0000000000006735↗
  34. Transitional Subtype of Circulating Tumor Cells in Early Post-Operative Period of 5-Year Survivors Following Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006925↗
  35. Transitional Type Circulating Tumor Cells Predict Systemic Recurrence and Support Risk Stratification for Chemotherapy After Resection of Pancreatic Ductal Ade… Co-author DOI 10.1097/sla.0000000000006998↗
  36. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  37. Reply to: Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Addressing Statistical and Methodological Concer… First author DOI 10.1200/jco-24-02598↗
  38. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… First author DOI 10.1245/s10434-024-16649-z↗
  39. Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Co-author DOI 10.1245/s10434-024-16673-z↗
  40. ASO Author Reflections: Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Early Recurrence and Patient-Tailored Management. Co-author DOI 10.1245/s10434-024-16810-8↗
  41. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Last author DOI 10.1245/s10434-025-17439-x↗
  42. ASO Author Reflections: The Impact of Adjuvant Therapy in the Era of Neoadjuvant Strategies for Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17788-7↗
  43. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  44. ASO Author Reflections: Old Truths, New Data: Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Requires Continued Surveillance. Co-author DOI 10.1245/s10434-025-18007-z↗
  45. The Impact of Social Determinants on Pancreatic Cancer Care in the United States. Co-author DOI 10.3390/cancers17121898↗
  46. The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Last author DOI 10.3390/cancers17193254↗
  47. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  48. Hidden in plain sight: commonly missed early signs of pancreatic cancer on CT. Co-author DOI 10.1007/s00261-024-04334-4↗
  49. The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Last author DOI 10.1016/j.pan.2024.06.004↗
  50. Diminishing calcifications as a potential predictor of pancreatic ductal adenocarcinoma arising in association with IPMN in patients with chronic pancreatitis. Co-author DOI 10.1016/j.radcr.2024.08.018↗

Closest collaborators

The 25 strongest of 328 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph R. Habib · 51 shared papers, 2020–2026 · strength 10.89
  2. Christopher Lee Wolfgang · 56 shared papers, 2016–2026 · strength 8.60
  3. Ingmar Florin Rompen · 31 shared papers, 2024–2026 · strength 6.71
  4. Jin Peng He · 47 shared papers, 2016–2026 · strength 6.44
  5. Greg D. Sacks · 24 shared papers, 2024–2026 · strength 5.41
  6. Christopher L. Wolfgang · 25 shared papers, 2021–2026 · strength 5.39
  7. Marc G. Besselink · 28 shared papers, 2019–2026 · strength 5.32
  8. Lois A. Daamen · 22 shared papers, 2024–2026 · strength 4.58
  9. Izaak Quintus Molenaar · 24 shared papers, 2018–2026 · strength 4.32
  10. Daniel Brock Hewitt · 20 shared papers, 2024–2026 · strength 4.22
  11. Kelly J. Lafaro · 23 shared papers, 2020–2026 · strength 3.49
  12. Richard Andrew Burkhart · 29 shared papers, 2018–2026 · strength 3.44
  13. Paul C. M. Andel · 17 shared papers, 2024–2026 · strength 3.43
  14. Omar Mahmud · 12 shared papers, 2024–2026 · strength 3.05
  15. Benedict Kinny‐Köster · 19 shared papers, 2020–2026 · strength 3.03
  16. Camila Hidalgo Salinas · 12 shared papers, 2025–2026 · strength 2.86
  17. Brady A. Campbell · 12 shared papers, 2024–2026 · strength 2.50
  18. William R. Burns · 19 shared papers, 2020–2025 · strength 2.47
  19. Elliot K. Fishman · 17 shared papers, 2017–2026 · strength 2.37
  20. Hjalmar C. van Santvoort · 11 shared papers, 2024–2026 · strength 2.10
  21. Mahip Grewal · 9 shared papers, 2024–2025 · strength 2.04
  22. Bas Groot Koerkamp · 11 shared papers, 2019–2026 · strength 1.98
  23. Ding Ding · 17 shared papers, 2018–2023 · strength 1.95
  24. Ralph H. Hruban · 14 shared papers, 2018–2026 · strength 1.91
  25. Thomas F. Stoop · 10 shared papers, 2024–2026 · strength 1.88

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.